Oppenheimer & Co. Inc. Increases Stake in Illumina, Inc. (ILMN)
Oppenheimer & Co. Inc. lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 88,829 shares of the life sciences company’s stock after purchasing an additional 1,444 shares during the period. Oppenheimer & Co. Inc. owned about 0.06% of Illumina worth $17,695,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. First Citizens Bank & Trust Co. lifted its position in Illumina by 0.4% during the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after acquiring an additional 12 shares during the last quarter. Puzo Michael J lifted its position in Illumina by 0.4% during the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after acquiring an additional 25 shares during the last quarter. Flagship Harbor Advisors LLC lifted its position in Illumina by 1.7% during the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after acquiring an additional 35 shares during the last quarter. Nordea Investment Management AB lifted its position in Illumina by 0.6% during the second quarter. Nordea Investment Management AB now owns 6,798 shares of the life sciences company’s stock valued at $1,180,000 after acquiring an additional 42 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC lifted its position in Illumina by 1.4% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock valued at $528,000 after acquiring an additional 43 shares during the last quarter. 90.76% of the stock is owned by hedge funds and other institutional investors.
In other news, SVP Mostafa Ronaghi sold 20,000 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $210.00, for a total value of $4,200,000.00. Following the sale, the senior vice president now owns 86,725 shares in the company, valued at $18,212,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 22,540 shares of the stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the completion of the sale, the director now owns 539,176 shares in the company, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. Insiders sold 172,446 shares of company stock worth $35,486,114 in the last quarter. Company insiders own 0.89% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up $3.30 during trading on Thursday, reaching $215.35. 692,100 shares of the company’s stock were exchanged, compared to its average volume of 954,919. The firm has a market cap of $30,959.30, a price-to-earnings ratio of 62.00, a price-to-earnings-growth ratio of 3.50 and a beta of 0.74. Illumina, Inc. has a twelve month low of $119.37 and a twelve month high of $215.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.97 earnings per share. equities research analysts anticipate that Illumina, Inc. will post 3.75 EPS for the current fiscal year.
A number of equities research analysts recently commented on ILMN shares. Barclays PLC increased their target price on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price for the company in a research report on Friday, October 27th. Canaccord Genuity reissued a “buy” rating and set a $230.00 target price (up previously from $215.00) on shares of Illumina in a research report on Thursday, October 12th. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $226.00 price target (up previously from $202.00) on shares of Illumina in a research note on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $200.88.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.